- Home
- ZIP vs XFOR Comparison
ZIP vs XFOR Comparison
Compare ZIP & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIP | XFOR |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.3M | 332.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZIP | XFOR |
|---|---|---|
| Price | $5.31 | $3.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.88 | ★ $28.50 |
| AVG Volume (30 Days) | ★ 806.3K | 571.7K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $448,299,000.00 | $33,979,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2925.74 |
| 52 Week Low | $3.35 | $1.35 |
| 52 Week High | $8.56 | $26.83 |
Technical Indicators
Market Signals| Indicator | ZIP | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 66.19 | 58.86 |
| Support Level | $5.12 | $3.05 |
| Resistance Level | $4.84 | $3.90 |
| Average True Range (ATR) | 0.29 | 0.27 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 86.05 | 87.25 |
Price Performance
Historical ComparisonAbout ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.